Aspergillosis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) No edit summary |
YazanDaaboul (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Aspergillosis}} | {{Aspergillosis}} | ||
{{CMG}}; | {{CMG}} {{AE}} {{YD}}; {{SSK}} | ||
==Overview== | ==Overview== | ||
The true incidence of aspergillosis is unknown since aspergillosis is not a reportable disease in the USA.<ref name="pmid23210682">{{cite journal| author=Denning DW, Pleuvry A, Cole DC| title=Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. | journal=Med Mycol | year= 2013 | volume= 51 | issue= 4 | pages= 361-70 | pmid=23210682 | doi=10.3109/13693786.2012.738312 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23210682 }} </ref> | |||
*The incidence of allergic bronchopulmonary aspergillosis is estimated to be 5 million worldwide.<ref name="pmid23210682">{{cite journal| author=Denning DW, Pleuvry A, Cole DC| title=Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. | journal=Med Mycol | year= 2013 | volume= 51 | issue= 4 | pages= 361-70 | pmid=23210682 | doi=10.3109/13693786.2012.738312 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23210682 }} </ref> In contrast, invasive aspergillosis is much less common. The incidence is thought to be approximately 1 to 2 cases per 100,000 individuals. There is no gender predilection for the development of aspergillosis. Individuals of all age groups may be affected with aspergillosis. Elderly patients with long-standing chronic lung diseases and neonates are more likely to develop aspergillosis. With the advancement of immunosuppressive therapy and higher rates of transplantation, the incidence and detection of aspergillosis is increasing in developed countries. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
*The true incidence of aspergillosis is unknown since aspergillosis is not a reportable disease in the USA. | *The true incidence of aspergillosis is unknown since aspergillosis is not a reportable disease in the USA.<ref name="pmid23210682">{{cite journal| author=Denning DW, Pleuvry A, Cole DC| title=Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. | journal=Med Mycol | year= 2013 | volume= 51 | issue= 4 | pages= 361-70 | pmid=23210682 | doi=10.3109/13693786.2012.738312 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23210682 }} </ref> | ||
*The incidence of allergic bronchopulmonary aspergillosis is estimated to be 5 million worldwide. | *The incidence of allergic bronchopulmonary aspergillosis is estimated to be 5 million worldwide.<ref name="pmid23210682">{{cite journal| author=Denning DW, Pleuvry A, Cole DC| title=Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. | journal=Med Mycol | year= 2013 | volume= 51 | issue= 4 | pages= 361-70 | pmid=23210682 | doi=10.3109/13693786.2012.738312 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23210682 }} </ref> | ||
*In contrast, invasive aspergillosis is much less common. The incidence is thought to be approximately | *Approximately 2.5% of adults who have asthma also have allergic bronchopulmonary aspergillosis.<ref name="pmid23210682">{{cite journal| author=Denning DW, Pleuvry A, Cole DC| title=Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. | journal=Med Mycol | year= 2013 | volume= 51 | issue= 4 | pages= 361-70 | pmid=23210682 | doi=10.3109/13693786.2012.738312 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23210682 }} </ref> | ||
*In contrast, invasive aspergillosis is much less common. The incidence is thought to be approximately 1 to 2 cases per 100,000 individuals.<ref name="pmid9827260">{{cite journal| author=Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL| title=The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. | journal=Clin Infect Dis | year= 1998 | volume= 27 | issue= 5 | pages= 1138-47 | pmid=9827260 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9827260 }} </ref> | |||
*Invasive aspergillosis is the most common type of fungal infection among stem cell transplant recipients (5% to 10%) and the second most common type of fungal infection among solid organ transplant recipients (5% to 25%).<ref name="pmid20218876">{{cite journal| author=Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A et al.| title=Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). | journal=Clin Infect Dis | year= 2010 | volume= 50 | issue= 8 | pages= 1101-11 | pmid=20218876 | doi=10.1086/651262 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20218876 }} </ref> | |||
==Mortality Rate== | |||
*The mortality rate of aspergillosis varies according to the clinical syndrome. | |||
:*Allergic bronchopulmonary aspergillosis and allergic ''Aspergillus'' sinusitis rarely results in mortality. | |||
:*In contrast, the mortality rate of invasive aspergillosis and chronic necrotizing pulmonary aspergillosis is high and may be up to 40% to 90%. | |||
=== | ==Gender== | ||
*There is no gender predilection for the development of aspergillosis. | |||
==Age== | |||
*Individuals of all age groups may be affected with aspergillosis. | |||
*Elderly patients with long-standing chronic lung diseases are more likely to develop aspergillosis. | |||
*Neonates are at increased risk of cutaneous aspergillosis. | |||
==Developed Countries== | |||
*With the advancement of immunosuppressive therapy and higher rates of transplantation, the incidence and detection of aspergillosis is increasing in developed countries. | |||
==References== | ==References== | ||
| Line 24: | Line 36: | ||
[[Category:Fungal diseases]] | [[Category:Fungal diseases]] | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
Revision as of 22:11, 8 February 2016
|
Aspergillosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Aspergillosis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Aspergillosis epidemiology and demographics |
|
Risk calculators and risk factors for Aspergillosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.
Overview
The true incidence of aspergillosis is unknown since aspergillosis is not a reportable disease in the USA.[1]
- The incidence of allergic bronchopulmonary aspergillosis is estimated to be 5 million worldwide.[1] In contrast, invasive aspergillosis is much less common. The incidence is thought to be approximately 1 to 2 cases per 100,000 individuals. There is no gender predilection for the development of aspergillosis. Individuals of all age groups may be affected with aspergillosis. Elderly patients with long-standing chronic lung diseases and neonates are more likely to develop aspergillosis. With the advancement of immunosuppressive therapy and higher rates of transplantation, the incidence and detection of aspergillosis is increasing in developed countries.
Epidemiology and Demographics
Incidence
- The true incidence of aspergillosis is unknown since aspergillosis is not a reportable disease in the USA.[1]
- The incidence of allergic bronchopulmonary aspergillosis is estimated to be 5 million worldwide.[1]
- Approximately 2.5% of adults who have asthma also have allergic bronchopulmonary aspergillosis.[1]
- In contrast, invasive aspergillosis is much less common. The incidence is thought to be approximately 1 to 2 cases per 100,000 individuals.[2]
- Invasive aspergillosis is the most common type of fungal infection among stem cell transplant recipients (5% to 10%) and the second most common type of fungal infection among solid organ transplant recipients (5% to 25%).[3]
Mortality Rate
- The mortality rate of aspergillosis varies according to the clinical syndrome.
- Allergic bronchopulmonary aspergillosis and allergic Aspergillus sinusitis rarely results in mortality.
- In contrast, the mortality rate of invasive aspergillosis and chronic necrotizing pulmonary aspergillosis is high and may be up to 40% to 90%.
Gender
- There is no gender predilection for the development of aspergillosis.
Age
- Individuals of all age groups may be affected with aspergillosis.
- Elderly patients with long-standing chronic lung diseases are more likely to develop aspergillosis.
- Neonates are at increased risk of cutaneous aspergillosis.
Developed Countries
- With the advancement of immunosuppressive therapy and higher rates of transplantation, the incidence and detection of aspergillosis is increasing in developed countries.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Denning DW, Pleuvry A, Cole DC (2013). "Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults". Med Mycol. 51 (4): 361–70. doi:10.3109/13693786.2012.738312. PMID 23210682.
- ↑ Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL (1998). "The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance". Clin Infect Dis. 27 (5): 1138–47. PMID 9827260.
- ↑ Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A; et al. (2010). "Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)". Clin Infect Dis. 50 (8): 1101–11. doi:10.1086/651262. PMID 20218876.